All lobbying filings

THE MCMANUS GROUP

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Represents the leading research-based pharmaceutical companies in the US.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $60,000.00 income · posted Jul 20, 2026

Official filing document

Bills named in this filing 4

S 832
EPIC Act of 2025
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act
HR 9504
Tax Exempt Hospital Transparency Act

Lobbying activity 3

Medicare/Medicaid

Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model

Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.

Taxation/Internal Revenue Code

Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.